Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Blood (2022) 140 (Supplement 1): 1313–1315.

https://doi.org/10.1182/blood-2022-166225

Published: 2022

Journal Articles

Decisional Role of Interim PET in Relapsed/Refractory Classical Hodgkin Lymphoma Treated with Begev Chemotherapy As First Salvage

Chiara Rusconi, Francesca Ricci, Vincenzo Marasco, Vittorio Ruggero Zilioli, Eleonora Calabretta, Anna Guidetti, Cristina Muzi, Federico Mazzon, Margherita Smania, Martina Sollini, Sara Iadecola, Erika Meli, Marcello Rodari, Emanuele Ravano, Roberto Cairoli, Paolo Corradini, Armando Santoro

Blood (2022) 140 (Supplement 1): 6581–6583.

https://doi.org/10.1182/blood-2022-165948

Published: 2022

Journal Articles

Circulating Tumor DNA Integrated with Interim [18F]FDG PET Is Highly Effective in Predicting Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma Treated with the Begev Regimen

Martina Di Trani, Francesca Ricci, Martina Sollini, Eleonora Calabretta, Vanessa Cristaldi, Stefanos Bonovas, Fabrizio Marino, Rita Mazza, Alessio Bruscaggin, Maria Cristina Pirosa, Arturo Chiti, Davide Rossi, Armando Santoro, Carmelo Carlo-Stella

Blood (2021) 138 (Supplement 1): 3504.

https://doi.org/10.1182/blood-2021-151362

Published: 2021

Journal Articles

The Infection-Driven Production/Secretion of Inflammatory Cytokines By Circulating Monocytes of Myelofibrosis Is Defective and Is Reactivated after In Vivo JAK1/2 Inhibition

Martina Barone, PhD, Francesca Ricci, BS, Marco Romano, PhD, Dorian Forte, PhD, Giuseppe Auteri, MD, Francesco Fabbri, PhD, Emanuela Ottaviani, Pierluigi Tazzari, MD, Nicola Vianelli, MD, Giovanni Martinelli, MD, Michele Cavo, Francesca Palandri, PhD MD, Lucia Catani

Blood (2019) 134 (Supplement_1): 1686.

https://doi.org/10.1182/blood-2019-127322

Published: 2019

Journal Articles

Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 131.

https://doi.org/10.1182/blood-2019-131096

Published: 2019

Journal Articles

The Malignant Hemopoietic Clone of Triple Negative Patients with Myelofibrosis Shows in Vitro Functional Defects but Is Highly Responsive to the Pro-Survival Signals of Circulating Autologous Microvesicles

Blood (2018) 132 (Supplement 1): 4334.

https://doi.org/10.1182/blood-2018-99-114507

Published: 2018

Journal Articles

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Armando Santoro, MD, Luca Castagna, MD, Massimo Magagnoli, MD, Stefania Bramanti, MD, Jacopo Mariotti, MD, Rita Mazza, MD, Lucia Morello, MD, Francesca Ricci, MD, Barbara Sarina, MD, Chiara De Philippis, MD, Simona Sica, MD, Marcello Rodari, MD, Martina Sollini, MD, Margarita Kirienko, MD, Laura Giordano, Arturo Chiti, MD, Paolo Corradini, MD, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2018-99-118127

Published: 2018

Journal Articles

Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study

Blood (2018) 132 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2018-99-115313

Published: 2018

Journal Articles

Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2 V617F Mutation, High Disease Burden and Ruxolitinib Response

Dorian Forte, PhD, Martina Barone, Francesca Ricci, Daria Sollazzo, Marco Romano, Emanuela Ottaviani, Giuseppe Auteri, Nicola Vianelli, Giovanni Martinelli, MD, Michele Cavo, MD, Pierluigi Tazzari, Francesca Palandri, PhD MD, Lucia Catani, MD

Blood (2017) 130 (Supplement 1): 4220.

https://doi.org/10.1182/blood.V130.Suppl_1.4220.4220

Published: 2017

Journal Articles

Molecular Profiling Of Blastic Plasmacytoid Dendritic CELL Neoplasm Reveals A Unique Pattern and Suggests Selective Sensitivity To NF-KB Pathway Inhibition

Blood (2013) 122 (21): 2502.

https://doi.org/10.1182/blood.V122.21.2502.2502

Published: 2013

Journal Articles

Characterization Of Genes and Pathways From The Comparison Between Bone Marrow B Cells As Well As Plasma Cells Of Waldenström Macroglobulinemia (WM) Vs. IgM Monoclonal Gammopathy Of Undetermined Significance (IgM-MGUS) Vs. Healthy Subjects Using Gene Profiling

Alessandra Trojani, Milena Lodola, Antonino Greco, Alessandra Tedeschi, MD, Barbara Di Camillo, Francesca Ricci, Anna Maria Frustaci, Mauro Turrini, Enrica Morra, MD

Blood (2013) 122 (21): 3772.

https://doi.org/10.1182/blood.V122.21.3772.3772

Published: 2013

Journal Articles

Microarray Identifies Different Molecular Signatures of Waldenstrom Macroglobulinemia (WM) Compared to IgM Monoclonal Gammopathy of Undetermined Significance (IgMMGUS)

Alessandra Trojani, Antonino Greco, Alessandra Tedeschi, MD, Barbara Di Camillo, Milena Lodola, Francesca Ricci, MD, Mauro Turrini, Marzia Varettoni, Sara Rattotti, Enrica Morra, MD

Blood (2012) 120 (21): 3495.

https://doi.org/10.1182/blood.V120.21.3495.3495

Published: 2012

Journal Articles

Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia.

Alessandra Tedeschi, MD, Davide Rossi, MD, Marta Coscia, MD, PhD, Eleonora Vismara, MD, Valeria Belsito Petrizzi, MD, Ester Orlandi, Nicola Cascavilla, Lydia Scarfò, MD, Marina Motta, MD, Candida Vitale, MD, Francesca Ricci, MD, Lorenzo De Paoli, MD, Alfonso Maria D'Arco, MD, Andrea Gallamini, MD, Gianluca Gaidano, MD, PhD, Enrica Morra, MD, Massimo Massaia, MD, Marco Montillo, MD

Blood (2012) 120 (21): 2898.

https://doi.org/10.1182/blood.V120.21.2898.2898

Published: 2012

Journal Articles

Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells

Francesca Chiarini, PhD, Cecilia Grimaldi, BS, Francesca Ricci, BS, Pierluigi Tazzari, MD, Ilaria Iacobucci, PhD, Giovanni Martinelli, MD, Pasqualepaolo Pagliaro, MD, James McCubrey, Sergio Amadori, MD, Alberto M Martelli, MD

Blood (2011) 118 (21): 2596.

https://doi.org/10.1182/blood.V118.21.2596.2596

Published: 2011

Journal Articles

Microarray Gene Expression Signature Indicates ARSD As a New Marker Associated with Igvh Mutational Status, ZAP-70 and Disease Progression in CLL,

Alessandra Trojani, Barbara Di Camillo, Alessandra Tedeschi, Lodola Milena, Simona Montesano, Francesca Ricci, Eleonora Vismara, Antonino Greco, Silvio Veronese, Anna Colosimo, Barbara Scarpati, Aldo Orlacchio, Sabata Martino, Chiara Colombo, Maria Angela Mura, Michele Nichelatti, Marco Montillo, Enrica Morra

Blood (2011) 118 (21): 3447.

https://doi.org/10.1182/blood.V118.21.3447.3447

Published: 2011

Journal Articles

Comparison Between FISH and Immunostimulatory Oligonucleotide-Induced Metaphase Cytogenetics in Previously Untreated CLL: Impact on Prognosis

Alessandra Tedeschi, Mariangela Mura, Eleonora Vismara, Silvia Soriani, Francesca Ricci, Elisa Roncoroni, Gabriella De Canal, Michele Nichelatti, Enrica Morra, Marco Montillo

Blood (2011) 118 (21): 4587.

https://doi.org/10.1182/blood.V118.21.4587.4587

Published: 2011

Journal Articles

Invasive Fungal Infections (IFI) In Lymphoproliferative Disorders: Epidemiology, Outcome and Prognostic Factors

Maria Luisa Pioltelli, Annamaria Nosari, Marta Riva, Laura Marbello, Laura Paris, Alessandra Tedeschi, Francesca Ricci, Eleonora Vismara, Speziale Valentina, Chiara Rusconi, Vittorio Ruggero Zilioli, Cristina Gabutti, Alfredo Molteni, Rosa Greco, Antonino Greco, Emanuele Ravano, Enrica Morra

Blood (2011) 118 (21): 4959.

https://doi.org/10.1182/blood.V118.21.4959.4959

Published: 2011

Journal Articles

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Marco Montillo, Alessandra Tedeschi, Valeria Belsito Petrizzi, Francesca Ricci, Monica Crugnola, Mauro Spriano, Pierangelo Spedini, Fiorella Ilariucci, Lilj Uziel, Immacolata Attolico, Eleonora Vismara, Angelo De Blasio, Alfonso Zaccaria, Enrica Morra

Blood (2011) 118 (15): 4079–4085.

https://doi.org/10.1182/blood-2011-05-351833

Published: 2011

Journal Articles

Targeted Inhibition of mTORC1 and mTORC2 by the Active-Site mTOR Inhibitors, PP-242 and OSI-027, Has Cytotoxic Effects In T-Cell Acute Lymphoblastic Leukemia

Camilla Evangelisti, PhD, Francesca Chiarini, PhD, Francesca Ricci, BS, Pierluigi Tazzari, MD, Andrea Pession, MD, PhD, James A McCubrey, PhD, Alberto M. Martelli, MD

Blood (2010) 116 (21): 3242.

https://doi.org/10.1182/blood.V116.21.3242.3242

Published: 2010

Journal Articles

AMP-Dependent Kinase/mTOR Complex 1 Signaling In T-Cell Acute Lymphoblastic Leukemia: Therapeutical Implications

Cecilia Grimaldi, BS, Francesca Chiarini, PhD, Francesca Ricci, BS, Pierluigi Tazzari, MD, Michela Battistelli, PhD, Elisabetta Falcieri, MD, Andrea Pession, MD, PhD, James McCubrey, PhD, Alberto M. Martelli, MD

Blood (2010) 116 (21): 3225.

https://doi.org/10.1182/blood.V116.21.3225.3225

Published: 2010

NARROW

Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Decisional Role of Interim PET in Relapsed/Refractory Classical Hodgkin Lymphoma Treated with Begev Chemotherapy As First Salvage

Circulating Tumor DNA Integrated with Interim [18F]FDG PET Is Highly Effective in Predicting Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma Treated with the Begev Regimen

The Infection-Driven Production/Secretion of Inflammatory Cytokines By Circulating Monocytes of Myelofibrosis Is Defective and Is Reactivated after In Vivo JAK1/2 Inhibition

Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

The Malignant Hemopoietic Clone of Triple Negative Patients with Myelofibrosis Shows in Vitro Functional Defects but Is Highly Responsive to the Pro-Survival Signals of Circulating Autologous Microvesicles

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study

Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2 V617F Mutation, High Disease Burden and Ruxolitinib Response

Molecular Profiling Of Blastic Plasmacytoid Dendritic CELL Neoplasm Reveals A Unique Pattern and Suggests Selective Sensitivity To NF-KB Pathway Inhibition

Characterization Of Genes and Pathways From The Comparison Between Bone Marrow B Cells As Well As Plasma Cells Of Waldenström Macroglobulinemia (WM) Vs. IgM Monoclonal Gammopathy Of Undetermined Significance (IgM-MGUS) Vs. Healthy Subjects Using Gene Profiling

Microarray Identifies Different Molecular Signatures of Waldenstrom Macroglobulinemia (WM) Compared to IgM Monoclonal Gammopathy of Undetermined Significance (IgMMGUS)

Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia.

Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells

Microarray Gene Expression Signature Indicates ARSD As a New Marker Associated with Igvh Mutational Status, ZAP-70 and Disease Progression in CLL,

Comparison Between FISH and Immunostimulatory Oligonucleotide-Induced Metaphase Cytogenetics in Previously Untreated CLL: Impact on Prognosis

Invasive Fungal Infections (IFI) In Lymphoproliferative Disorders: Epidemiology, Outcome and Prognostic Factors

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Targeted Inhibition of mTORC1 and mTORC2 by the Active-Site mTOR Inhibitors, PP-242 and OSI-027, Has Cytotoxic Effects In T-Cell Acute Lymphoblastic Leukemia

AMP-Dependent Kinase/mTOR Complex 1 Signaling In T-Cell Acute Lymphoblastic Leukemia: Therapeutical Implications

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only